化合物 ENMD-1198|T15234|TargetMol

價(jià)格	￥13800	￥10600	￥17500
包裝	50mg	25mg	100mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 ENMD-1198	英文名稱:ENMD-1198
CAS:864668-87-1	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
產(chǎn)品類別: 抑制劑
貨號(hào): T15234

Product Introduction

Bioactivity

名稱	ENMD-1198
描述	ENMD-119 is a 2-methoxyestradiol analog with antiproliferative and antiangiogenic activity. It is suitable for inhibiting HIF-1α and STAT3 in human HCC cells.
體外活性	ENMD-1198 inhibits the proliferation of endothelial cell HMEC-1 and BMH29L (IC50: 0.4 μM and 3.8 μM) and it also significantly inhibits capillary tube formation from 0.1 μM and suppresses endothelial cell morphogenesis at 1 μM. ENMD-1198 inhibits endothelial cell motility and endothelial cell migration and inhibits MDA-BO2 cancer cell viability (IC50: approximately 0.8 μM). ENMD-1198 also inhibits the phosphorylation of MAPK/Erk, PI-3K/Akt, and FAK. ENMD-1198 (0.5 μM) inhibits the formation of capillary tubes in HMEC-1 cells. Moreover, ENMD-1198 at the IC50 for cell proliferation causes a significant decrease in VEGFR-2 expression both in the presence and in the absence of serum. ENMD-1198 rapidly causes extensive microtubule depolymerization and accumulation of actin stress fibers and large focal adhesions [1]. ENMD-1198 has both an antiangiogenic effect and a vascular disruptive effect in vitro. ENMD-1198 reduces the viability of RAW264.7 osteoclast precursor cells and inhibits PTHrP-stimulated bone resorption. ENMD-1198 shows inhibitory activity against RAW264 (IC50: approximately 0.4 μM) and is shown to be 4 times more potent than 2ME2 (IC50 appro 1.6 μM) [2]. The activation of HIF-1α and STAT3 is dramatically reduced by ENMD-1198, which leads to lower VEGF mRNA expression. In addition, the tumor cell migratory and invasive properties are obviously inhibited [3].
體內(nèi)活性	ENMD-1198 treatment protects the bone against tumor-induced osteolysis in vivo [2]. ENMD-1198 (200 mg/kg/d, peroral gavage)-based combination treatments decrease tumor burden but do not eradicate the tumor in mice. ENMD-1198 (200 mg/kg/day, p.o.) leads to a significant reduction in tumor growth, tumor vascularization, and numbers of proliferating tumor cells [3].
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
關(guān)鍵字	ENMD 119 \| ENMD119 \| IRC-110160 \| IRC110160 \| ENMD1198 \| ENMD-1198
相關(guān)產(chǎn)品	Acriflavine Hydrochloride \| Artesunate \| Nifuroxazide \| Hydroxycitric acid tripotassium hydrate \| Diosgenin \| Niclosamide olamine \| CASIN \| Fludarabine \| Cinnamaldehyde \| Niclosamide \| Alantolactone \| Balsalazide sodium hydrate

關(guān)鍵字： IRC 110160|||ENMD-119|||ENMD 1198|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù)，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	589.8595萬(wàn)人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	中間體,天然產(chǎn)物,生物化工,化學(xué)試劑,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 1年

公司成立：12年
注冊(cè)資本：589.8595萬(wàn)人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：抑制劑&激動(dòng)劑，天然產(chǎn)物，重組蛋白，化合物庫(kù)，技術(shù)服務(wù)
公司地址：上海市靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

BTC, Mouse, 重組蛋白 (His)|TMPJ-00058|TargetMol

￥17400

化合物 JNJ-40255293|T24209|TargetMol

￥17500

MBL2, Mouse, 重組蛋白|TMPJ-00133|TargetMol

￥17400